Core Viewpoint - Suzhou Zelgen Biopharmaceutical Co., Ltd. (Zelgen Pharma) has officially submitted its application for listing on the Hong Kong Stock Exchange, aiming to enhance its international brand recognition and support its global business strategy, despite recent actions that raise questions about its commitment to internationalization [1] Financial Performance - Zelgen Pharma has not yet achieved profitability since its IPO on the STAR Market in 2020, but its losses have been decreasing year by year. Revenue for 2022, 2023, and 2024 is reported at 302 million, 386 million, and 533 million yuan respectively, while losses for the same periods are 457 million, 279 million, and 138 million yuan [2] - In the first three quarters of 2025, the company reported revenue of 593 million yuan, a year-on-year increase of 54.49%, with losses amounting to 93.42 million yuan [2] - The company's revenue primarily comes from three approved products, with significant sales expenses that have risen alongside revenue, indicating a focus on market expansion [2] Capital Operations - Zelgen Pharma has engaged in frequent capital operations, raising 2.026 billion yuan during its IPO and an additional 1.2 billion yuan through a private placement in 2023. The company has utilized 1.677 billion yuan of the IPO funds and 406 million yuan of the private placement funds for new drug research projects [3] - The company has also proposed to raise up to 300 million yuan through a simplified procedure for issuing shares to specific investors [3] - A notable portion of the raised funds has been redirected, with 25.38% of IPO funds and 19.88% of private placement funds having their purposes changed [3] Debt Situation - The company's interest-bearing debt has been on the rise, with short-term loans increasing from 391 million yuan in 2022 to 967 million yuan in the first three quarters of 2025, and long-term loans fluctuating during the same period [4] Internationalization Strategy - Despite the importance of internationalization for Zelgen Pharma, the company recently canceled its overseas subsidiary GENSUN, which was seen as a key component of its international strategy. This decision came after the company had previously acquired shares in GENSUN using its own funds [5][6] - GENSUN, established in the U.S. for new drug research, has been unprofitable since its inception, yet the company valued it at approximately 90.28 million USD during acquisitions [6] - The company has reduced its investment in an international clinical trial project, indicating a shift in focus due to competitive pressures in the market [7]

Macro Strategy - The core view indicates that actual interest rates remain the key anchor for gold prices, with fluctuations driven by macroeconomic policies and geopolitical factors [1][11] - In November, gold prices are expected to be influenced by geopolitical situations, trade negotiations, and macro policies, with a potential for continued high-level fluctuations [1][11] - The CME interest rate futures suggest a widespread expectation of a 25 basis point rate cut by the Federal Reserve in December, which may support gold prices [1][11] Fixed Income Strategy - The report discusses a trading strategy of "long old bonds and short new bonds" based on the behavior of active bond spreads, which typically exhibit a jump during the switching process [2][12] - The active bond spread trading strategy remains profitable, with the maximum spread observed at 9.8 basis points since 2023, indicating a favorable trading environment [2][12] Food and Beverage Industry - The beer sector is currently viewed as being at a bottoming phase, with expectations for demand recovery driven by macro policy changes and improved fundamentals in 2024 [4][14] - The report highlights that the beer sector's revenue for the first three quarters of 2025 reached 617.26 billion yuan, with a year-on-year growth of 1.99% [4][15] - Key players such as Qingdao Beer and Yanjing Beer are expected to perform well, with a focus on high-growth segments and defensive strategies [4][15] Healthcare Products Industry - The healthcare products sector showed a year-on-year revenue growth of 18% and a net profit increase of 122% in Q3 2025, indicating a positive trend despite individual stock variations [16][17] - Companies like Tongrentang and Minsheng Health are highlighted for their strong performance and growth potential in the healthcare market [16][17] Nonferrous Metals Industry - The report notes that industrial metals are experiencing high-level fluctuations, with copper prices expected to strengthen after a period of consolidation due to supply disruptions and improved macro sentiment [5][19] - Aluminum prices have shown an upward trend, supported by supply stability and increased demand, particularly in the context of geopolitical developments [5][19] Media Industry - The media sector reported a revenue of 1,279 billion yuan in Q3 2025, reflecting a 7% year-on-year increase, with the gaming sector showing particularly strong performance [6][20] - The gaming segment's net profit grew by 76% year-on-year, driven by successful product launches and a stable revenue growth trajectory [6][20]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The 2025 National Medical Insurance negotiation has commenced, with a focus on innovative drugs and a significant increase in the number and quality of applications for drugs outside the basic medical insurance directory [17][18]. - The report highlights a robust performance of the pharmaceutical sector, with the A-share pharmaceutical index showing a year-to-date increase of 21.1%, outperforming the CSI 300 index by 3.17% [4][9]. - The report emphasizes the long-term growth potential of China's innovative drug market, driven by a large patient pool, favorable policies, and a strong pipeline of innovative drugs [16]. Summary by Sections 1. Industry Performance - The A-share pharmaceutical index has increased by 1.31% this week and 21.1% year-to-date, with significant outperformance against the CSI 300 index [4][9]. - The Hang Seng Healthcare Index has shown a year-to-date increase of 73.53%, outperforming the Hang Seng Technology Index by 40.06% [4][9]. 2. R&D Progress and Company Dynamics - Pfizer has initiated two global Phase III clinical studies for PD-1/VEGF dual antibodies, targeting non-small cell lung cancer and colorectal cancer [4]. - The report notes that 310 generic names have passed the formal review for inclusion outside the basic medical insurance directory, marking a 24.5% increase from 2024 [18]. 3. Industry Insights and Regulatory Developments - The report ranks favored sub-industries as follows: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [10][12]. - The report identifies key companies to watch, including Innovent Biologics, BeiGene, and Hengrui Medicine, among others, for their strong clinical competitiveness [12][18]. 4. Market Review - The report indicates that the pharmaceutical sector's adjustment has narrowed, with some sub-industries experiencing slight rebounds [4][9]. - The report provides a detailed overview of stock performance, highlighting significant gainers and losers in the A-share and H-share markets [4][9].

Group 1: Company Highlights - Mindray Medical has launched the world's first clinically implemented critical care large model, named Qiyuan Critical Care Model, and established a subsidiary for animal healthcare [1] - In the field of medical imaging, Mindray's "Ruiying Cloud++" has partnered with DeepSeek to officially release the "Ruiying·AI+" solution [1] - Zai Lab achieved a revenue of 376 million yuan in the first half of 2025, representing a year-on-year growth of 56%, driven by increased drug sales [1] - Zai Lab's recombinant human thrombin has been included in medical insurance, boosting sales, and the company is advancing multiple clinical trials for various tumors [1] - Zai Lab's NDA for Jikaxitini tablets for severe alopecia has been accepted, and several Phase III trials in the autoimmune field are under observation [1] - Dia Group reported a revenue of 786 million yuan in the first half of 2025, a year-on-year increase of 0.97%, with a net profit of 76 million yuan, up 131.61% [2] - The average sales of upgraded stores in the red gold theme have increased by approximately 36% year-on-year [2] - Dia Group plans to implement an equity incentive plan annually over four years and is expanding its presence in overseas markets, particularly in Paris and the U.S. [2] Group 2: Institutional Overview - Tongxin Investment, established in January 2014, is a distinctive sunshine private equity firm with a registered capital of 10 million yuan [3] - The firm is recognized for being one of the few sunshine private equity firms founded by top analysts from New Fortune and has a strong focus on consumer investment [3]

Group 1 - The core viewpoint of the article is that Huazhong Securities has given a "buy" rating to Zai Lab (688266.SH) based on its improving financial condition and ongoing commercialization efforts [1] - The financial status of Zai Lab is reported to be continuously improving, with balanced and stable expenditures [1] - Zai Lab is making steady progress in its commercialization process, particularly with the drug Gika Xiqi (吉卡昔替尼片) preparing for medical insurance negotiations [1] - The company is advancing multiple specific antibodies into clinical trials, focusing on combination therapies targeting various pathways [1]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future investment returns [10]. Core Insights - The company reported a revenue of 376 million yuan for the first half of 2025, representing a year-on-year increase of 56.07%. However, the net profit attributable to the parent company was a loss of 73 million yuan, a decrease of 9.42% year-on-year [5]. - The company is advancing its commercialization process, with the drug Jika Xiqi (盐酸吉卡昔替尼) preparing for negotiations to be included in the national medical insurance directory [7]. - The company has made significant progress in its innovative pipeline, with multiple bispecific antibodies entering clinical trials and showing promising results [8]. Financial Performance - The overall gross margin for the first half of the year was 89.67%, a decrease of 3.07 percentage points year-on-year. The operating cash flow was negative 17 million yuan, a decline of 115.12% year-on-year [6]. - The company expects revenues of 900 million yuan, 1.65 billion yuan, and 2.41 billion yuan for 2025, 2026, and 2027, respectively, with corresponding year-on-year growth rates of 68.7%, 83.2%, and 46.2% [10]. - The projected net profit attributable to the parent company for the same years is 73 million yuan, 530 million yuan, and 1.02 billion yuan, with year-on-year growth rates of 152.7%, 628.6%, and 93.1% [10]. Product Development - The company’s drug ZGGS15 (LAG3/TIGIT) has received IND approval in both China and the US, marking it as the first of its kind to enter clinical research [8]. - The drug Zepu Ping (盐酸吉卡昔替尼片) was approved for market entry in May 2025 and is set to participate in the national medical insurance negotiations [9]. - The company has established a commercial presence in over 1,200 hospitals and 2,200 pharmacies for its product Zepu Sheng (甲磺酸多纳非尼片) [9].

Core Insights - The company reported a revenue of 530 million yuan in 2024, representing a 37.9% increase, while the net profit attributable to shareholders was -140 million yuan, significantly narrowing from -280 million yuan in 2023 [1] - In Q1 2025, the revenue reached 170 million yuan, marking a 54.9% increase [1] - The commercialization of the drug Donafenib has progressed steadily, with over 1,100 hospitals and nearly 1,000 pharmacies covered by the end of 2024 [1] Financial Performance - The company achieved a revenue of 530 million yuan in 2024, driven by the steady advancement of Donafenib's commercialization [1] - The company received a licensing fee of 340 million yuan from Penglai Nuo Kang Pharmaceutical Co., Ltd. for exclusive marketing rights [1] - The company is making progress in the new drug application review for Jikaxitini tablets for treating high-risk myelofibrosis [1] R&D Progress - The company focused on core product development, achieving several milestone advancements, including successful Phase III clinical trials for Jikaxitini tablets in severe alopecia areata [2] - The safety and tolerability of Jikaxitini in treating severe alopecia areata patients were found to be good [2] - The company has completed pre-NDA communication with the CDE [2] Competitive Advantage - The antibody platform's advantages are becoming more pronounced, with multiple drugs progressing well [3] - ZG006 received orphan drug designation from the FDA for treating small cell lung cancer, showing good tolerability and safety in Phase I clinical trials [3] - The company expects substantial revenue growth, forecasting revenues of 810 million, 1.44 billion, and 2.08 billion yuan for 2025, 2026, and 2027, respectively [3]